The treatment of adult GHD with recombinant human growth hormone (rhGH) is commenced in patients with severe GH deficiency, a ‘Quality of life assessment of growth hormone deficiency in adults’ (QoL-AGHDA) score of at least 11 and are receiving treatment for other pituitary hormone deficiencies. The gene discussed is GH1; the disease is hypopituitarism.